Trials / Unknown
UnknownNCT04448353
Carotid Risk Prediction (CRISP) Consortium
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Elucid Bioimaging Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Develop adverse event prediction and plaque phenotype classification models for patients with known or suspected carotid artery disease.
Detailed description
Develop adverse event prediction and plaque phenotype classification models using plaque morphology and composition assessment of CTA which has been validated by histology, applied to representative cohort of patients. Generalizability of models is enhanced by using validated rather than only raw image inputs. Demographic, clinical, and outcome data is collected for enrolled patients as well as information on events and interventions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | vascuCAP | adverse event and phenotype classification model |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2021-12-15
- Completion
- 2022-04-30
- First posted
- 2020-06-25
- Last updated
- 2021-02-04
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04448353. Inclusion in this directory is not an endorsement.